Plain-English translation of NCT05580666 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
The REVIVE trial is testing whether azithromycin, a common antibiotic, can help improve survival and health outcomes in adults with advanced HIV disease. Participants will take either azithromycin or a placebo (inactive pill) once daily for 28 days while also starting or adjusting their HIV medications. Researchers will follow everyone for 48 weeks to see whether the antibiotic helps prevent serious infections and complications.
People with very advanced HIV disease — before they start strong HIV medications — are at extremely high risk of dangerous infections and death. This medication is already used in some HIV programs to prevent infections, but doctors aren't sure if it really helps improve survival, so this large trial will provide that answer.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to take either azithromycin or a matching placebo tablet once daily for 28 days — neither you nor the study staff will know which one you're taking. You'll also start or adjust your regular HIV medications during this time. The study team will see you for check-ups and blood tests at regular intervals over 48 weeks (about one year) to monitor your health, CD4 count, and any infections or side effects.
AI-generated summary from trial data · Jul 11, 2026 · Not medical advice
Côte d’Ivoire
Ethiopia